MedPath

A Study of 1592U89 Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs

Phase 2
Completed
Conditions
HIV Infections
Registration Number
NCT00002364
Lead Sponsor
Glaxo Wellcome
Brief Summary

To obtain preliminary evidence of antiretroviral activity of 1592U89 when administered in combination with other specific NRTI agents in NRTI experienced patients and to assess the safety and tolerance of multiple oral doses of 1592U89 when administered in combination with specific marketed NRTIs.

Detailed Description

Patients will all receive oral doses of 1592U89 in combination with protocol specific current antiretroviral therapy. The treatment groups will be assigned based on each subject's previous NRTI experience.

The study medication is self administered and all evaluations will be performed on an outpatient basis. Patients will be seen at day 0 and weeks 2, 4, 12, 16, 20 and 24.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (8)

Marin County Specialty Clinic

πŸ‡ΊπŸ‡Έ

Greenbrae, California, United States

Kraus Med Partners

πŸ‡ΊπŸ‡Έ

Los Angeles, California, United States

ViRx Inc

πŸ‡ΊπŸ‡Έ

San Francisco, California, United States

IDC Research Initiative

πŸ‡ΊπŸ‡Έ

Altamonte Springs, Florida, United States

North Broward Hosp District

πŸ‡ΊπŸ‡Έ

Fort Lauderdale, Florida, United States

AIDS Research Consortium of Atlanta

πŸ‡ΊπŸ‡Έ

Atlanta, Georgia, United States

Univ of Kentucky Med Ctr

πŸ‡ΊπŸ‡Έ

Lexington, Kentucky, United States

Beth Israel Med Ctr

πŸ‡ΊπŸ‡Έ

New York, New York, United States

Marin County Specialty Clinic
πŸ‡ΊπŸ‡ΈGreenbrae, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.